Clinical Trial Update: Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial of fosaprepitant for preventing chemotherapy-related nausea and vomiting in patients receiving high-dose interleukin-2 for metastatic melanoma or …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Renal Cell Carcinoma

Drugs mentioned

• FOSAPREPITANT (FOSAPREPITANT DIMEGLUMINE)

Snippet

Sponsor: St. Louis University | Conditions: Chemotherapy-induced Nausea and Vomiting | Phase 2 | Status: TERMINATED | Results posted: 2018-05-04